Madrigal (NASDAQ: MDGL) insiders detail recent multi-million stock sales

Rhea-AI Filing Summary

Madrigal Pharmaceuticals insiders filed a Rule 144 notice covering the planned sale of 647 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq Stock Market, with an aggregate market value of 310851.15. The 647 shares were acquired on 01/23/2026 via a restricted stock unit grant from the issuer, vesting the same day.

The notice also lists prior sales over the past three months. REBECCA A TAUB sold 2238 shares of common stock on 01/20/2026 for gross proceeds of 1098343.26, 18650 shares on 01/09/2026 for 9749391.94, and 18650 shares on 12/10/2025 for 10297573.26. Sales for PAUL A FRIEDMAN include 24800 shares on 01/09/2026 for 12963304.72 and 24800 shares on 12/10/2025 for 13694158.24. The signer represents they are not aware of undisclosed material adverse information about Madrigal’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	647	310851.15	22711420	01/26/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	Restricted Stock Unit Grant	Issuer			647	01/23/2026	Vesting of Restricted Stock Units

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
REBECCA A TAUB c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	01/20/2026	2238	1098343.26
REBECCA A TAUB c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	01/09/2026	18650	9749391.94
REBECCA A TAUB c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	12/10/2025	18650	10297573.26
Sales for PAUL A FRIEDMAN c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	01/09/2026	24800	12963304.72
Sales for PAUL A FRIEDMAN c/o Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 200 West Conshohocken PA 19428	Common Stock	12/10/2025	24800	13694158.24

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider stock sale is covered in this Madrigal (MDGL) Rule 144 notice?

The notice covers the planned sale of 647 shares of Madrigal Pharmaceuticals common stock, to be sold through Morgan Stanley Smith Barney LLC on the Nasdaq Stock Market, with an aggregate market value of 310851.15 listed in the filing.

How were the 647 Madrigal (MDGL) shares in this Form 144 acquired?

The 647 shares of common stock were acquired on 01/23/2026 via a restricted stock unit grant from the issuer, with the filing describing the nature of payment as the vesting of restricted stock units on the same date.

Which broker is handling the planned Madrigal (MDGL) share sale?

The planned sale of 647 shares of Madrigal common stock is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, and the shares are listed on the Nasdaq Stock Market.

What Madrigal (MDGL) insider sales by Rebecca A. Taub are disclosed for the past 3 months?

The filing reports that REBECCA A TAUB sold Madrigal common stock as follows: 2238 shares on 01/20/2026 for gross proceeds of 1098343.26, 18650 shares on 01/09/2026 for 9749391.94, and 18650 shares on 12/10/2025 for 10297573.26.

What Madrigal (MDGL) insider sales for Paul A. Friedman are listed in this notice?

The notice lists sales for PAUL A FRIEDMAN of Madrigal common stock: 24800 shares on 01/09/2026 for gross proceeds of 12963304.72, and 24800 shares on 12/10/2025 for 13694158.24, with the address given as c/o Madrigal Pharmaceuticals, Inc., West Conshohocken, PA.

What representation does the insider make about Madrigal (MDGL) information in this Rule 144 filing?

The person for whose account the securities are to be sold represents by signing that they do not know any material adverse information about the current and prospective operations of Madrigal Pharmaceuticals that has not been publicly disclosed, as stated in the notice.